

March 07, 2023

To,
The General Manager,
Listing Operation,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip code: 540737

Dear Sir / Madam,

Subject: Newspaper Publication for Right Issue

Please find enclosed herewith Newspaper Publication as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 published, In accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 containing Advertisements for basis of right issue in the following newspapers on Tuesday, March 07, 2023

1. Business Standard (English)
2. Business Standard (Hindi)
3. Dhabkar (Gujarati)

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For Shree Ganesh Remedies Limited

Sunny Narwani
Company Secretary & Compliance Officer

Encl.: As above

Cautious optimism around building material sector

Volatile input costs and fears of global slowdown make demand projections uncertain: Experts

NIKITA VASHISHT
New Delhi, 6 March



SUPREME INDUSTRIES STANDS TALL

Stock	CMP* (in ₹)	% change YTD
Asian Paints	2,867.0	-7.3
Tata Steel	105.7	-6.2
Kajaria Ceramics	1,084.1	-6.3
Greenlam Industries	305.9	-5.0
Prince Pipes & Fittings	576.3	-3.2
Astral Pipes	1,923.1	-2.1
Supreme Industries	2,699.2	10.2
BSE Sensex	60,224.5	-1.0
NSE Nifty50	17,711.5	-2.2

Note: *CMP is current market price (as on March 6)
Source: Bloomberg, exchanges

Compiled by BS Research Bureau

upwards to ₹79,000 crore for FY24, from ₹48,000 crore for FY23. According to a report by Prabhudas Lilladher, the Indian real estate sector grew at 10 per cent compound annual growth rate (CAGR), from \$50 billion in 2008 to \$120 billion in 2017, and is expected to see 17 per cent CAGR to \$1 trillion by 2030.

Since demand for home building material is directly correlated to the real estate market's growth, the combined market size of the allied sector could touch ₹2.7 trillion by 2025-26, from ₹1.3 trillion in 2021-22, said the brokerage.

However, volatile input costs, amid renewed geopolitical tensions, may cloud near-term outlook. Among the lot, plastic pipe

companies are the most preferred pick across brokerages as companies are aggressively focusing on innovation, product launches, and market opportunities beyond plastic pipes and fittings.

Astral Pipes has entered the bathware industry, which has a market size of ₹15,000 crore versus the plastic pipe market size of ₹38,500 crore.

Prince Pipes and Fittings, too, has guided for the launch of its bathware product portfolio by March-April of this calendar year (CY23).

"Organised players account for 67 per cent of the total plastic pipe market. The industry grew at 10-12 per cent CAGR between 2014-15 and 2019-20, with

demand likely to expand at 12-14 per cent CAGR between 2020-21 and 2024-25 (FY25) to reach more than ₹60,000 crore by FY25 amid increase in government spending towards irrigation, water supply and sanitation projects, urban infrastructure, and replacement demand. We initiate coverage on Astral Pipes, Finolex Industries, Prince Pipes and Fittings, and Supreme Industries with a 'buy' rating," said Prabhudas Lilladher.

Moreover, strong growth in a fixed asset investment upcycle across industrial, infrastructure, and residential-end markets, according to equity research analyst Shrinidhi Karlekar of HSBC Securities and Capital Markets (India), will drive double-digit revenue growth for Polycab India and KEI Industries, within the cables and wires segment, in CY23 and FY24. Metals, too, remain a bright spot as the prices of coking coal — one of the key input raw materials — have plunged over the past few days with easing supply concerns.

"The demand for long steel has remained firm on the back of the government's push to fast-track infrastructure projects. As Indian markets slowly scout European markets, after the roll-back of export duty and constraints faced by Turkey after the earthquake, the near-term outlook seems positive with price hikes expected in the coming weeks," said Motilal Oswal Financial Services.

It has a 'neutral' rating on Tata Steel, JSW Steel, and Vedanta, and a 'buy' on Hindalco and Jindal Steel & Power.

Analysts remain cautious on cement, wood panel, and tiles as elevated input costs and weak export markets may dent sustainable volume and margin recovery.

Abating pricing pressure in US mkt good news for pharma funds

SANJAY KUMAR SINGH

In contrast with their strong performance in 2020 and 2021, pharmaceutical and healthcare funds experienced a decline in 2022, with returns plummeting by an average 9.8 per cent. This trend has continued in the current year, with year-to-date return remaining in the negative (-4.9 per cent). In the past three months, pharma funds have been hit hard, experiencing a 7.9 per cent decline.

Post-pandemic blues

A number of factors affected the sector's earnings in the post-Covid-19 period. "Excess stocking in the supply chain, rise in raw material costs due to China-led shortages, and weak pricing in the US market are the key reasons for the weakness witnessed in the near term," says Sailesh Raj Bhan, chief investment officer-equity investments, Nippon India Mutual Fund. He adds that some of these trends are bottoming out, and this is likely to be reflected in improved earnings over the next few quarters.

Dharmesh Kakkad, fund manager, ICICI Prudential Asset Management Company (AMC) attributes the sector's recent underperformance to US Food and Drug Administration's (USFDA) observations (the US regulator pulled up some of the Indian pharma majors after inspecting their factories) and stretched approval timelines for complex generic products in the US. According to him, the lowering of the drug price ceiling under the Drug Price Control Order (in the domestic market) was also responsible for the sector coming under pressure.


Chirag Dagli, fund manager, DSP Mutual Fund, says that hospital and pathology stocks, which did well during Covid-19 and supported the performance of these funds, have either corrected or have been flat.

Positives on the horizon


Fund managers, however, remain upbeat on the medium to long term prospects of the sector.

Export markets: According to Dagli, the US business is turning around,

UNDERPERFORMER IN SHORT TERM, STELLAR LONG-TERM RECORD



POOR RETURNS IN 2022 AND THIS YEAR SO FAR



Returns are for regular funds
Source: Morningstar AWS

with third-quarter numbers showing reasonable growth for most players. While the recent growth was partly due to the flu season in the US, the trend is likely to continue. "New product launches are in the pipeline. The trend of double-digit price erosion in the base business is also beginning to normalise to more manageable levels of high single digit," adds Dagli.

The existing players are rationalising the pricing of their US generic portfolios. Says Kakkad: "A few players are also exiting the market, given that segment profitability has deteriorated considerably." These developments could result in improved pricing power for Indian companies.

According to Bhan, exports to non-US markets like emerging markets and Africa are also improving. **Domestic market:** Dagli points out that in the domestic formulations market, starting from April 2023, products under the National List of Essential Medicines (NLEM) will be allowed to take wholesale price index

(WPI)-linked price hikes. "This will affect about 20-25 per cent of the domestic market," he says.

The share of domestic branded business in overall profit share has been increasing, according to Bhan. He expects this trend to continue with the population of those aged above 50 likely to rise sharply. Hospitals have experienced normalisation of their business. Dagli believes occupancies will increase in the first and second quarters of the next financial year. Bhan is of the view that the increased adoption of health insurance during Covid-19 will be a positive for the hospital sector over the medium term. According to Kakkad, companies have indicated that raw material prices have begun to soften.



Take limited exposure

The sector is reasonably valued after its relative underperformance vis-à-vis the broader market over the past 12-18 months. "It offers the prospect of reasonable growth along with improved earnings possibilities," says Bhan. Sector funds, however, are less diversified

than diversified-equity funds, and hence carry higher risk. Viral Bhatt, founder, Money Mantra warns that regulatory changes have the potential to impact their returns.

Investors who have knowledge of this sector, or have the ability to do research, may enter these funds. "Enter with a horizon of five-seven years or more. Exposure shouldn't exceed 10 per cent of your total equity investment," says Bhatt.



(This is an Advertisement for information purposes only and not for publication or distribution or release outside India and is not an Offer Document)

SHREE GANESH REMEDIES LIMITED (CIN : L24230GJ1995PLC025661)

Our Company was originally incorporated as Shree Ganesh Remedies Private Limited at Ahmedabad, Gujarat as a Private Limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated April 27, 1995 bearing registration number 025661 issued by Assistant Registrar of Companies, Gujarat, Dadra & Nagar Haveli. Subsequently our Company was converted into a Public Limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on July 12, 2017 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Gujarat, Ahmedabad dated July 28, 2017 and to consequent legal status the name of our Company was changed to "Shree Ganesh Remedies Limited". Our Company was originally listed on SME platform of BSE Limited on October 13, 2017, subsequently migrated on the Main Board platform of BSE Limited vide their notice dated November 23, 2020. The Corporate Identification Number is L24230GJ1995PLC025661. For further details of our Company, please see section titled as "General Information" beginning on page 39 of the Letter of Offer.

Reg. Off. : Plot no. 6011, G.I.D.C. Ankleshwar, Gujarat - 393002, India. • Tel: +91 7574976076 • E-mail : investors@ganeshremedies.com • Web : www.ganeshremedies.com
Contact Person : Sunnykumar Narwani, Company Secretary & Compliance Officer • Corporate Identification Number : L24230GJ1995PLC025661

PROMOTERS OF OUR COMPANY ARE CHANDULAL KOTHIA, ASHOKKUMAR KOTHIA, MANUBHAI KOTHIA, GUNJANBHAI KOTHIA & HANSHABEN KOTHIA

ISSUE OF UPTO 8,40,471 PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF 10/- EACH ("RIGHTS EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF 225/- EACH PER RIGHTS EQUITY SHARE (INCLUDING PREMIUM OF 215/- PER EQUITY SHARE) (THE "ISSUE PRICE"), AGGREGATING UPTO 1891.06 LAKHS/- @ ON A RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 7 RIGHTS EQUITY SHARE(S) FOR EVERY 100 FULLY PAID-UP EQUITY SHARE(S) HELD BY THE EXISTING EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON FEBRUARY 03, 2023 (THE "ISSUE"). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARES IS 225/- WHICH IS 22.5 TIMES THE FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE 167 OF THE LETTER OF OFFER.

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on Monday, February 13, 2023 and closed on Tuesday, February 21, 2023 and the last date for On Market Renunciation of Rights Entitlements was Wednesday, February 15, 2023. Out of the total 443 Applications for 8,59,451 Rights Equity Shares, 69 Applications for 5,957 Rights Equity Shares were rejected due to technical reasons. The total number of valid Applications received were 374 for 8,53,494 Rights Equity Shares. In accordance with the Letter of Offer and the Basis of Allotment finalized on February 27, 2023 in consultation with BSE Limited ("BSE"), the Designated Stock Exchange, the Lead Manager to the Issue and the Registrar to the Issue. The Rights Issue Committee of the Company on February 28, 2023 has approved the allotment of 8,40,471 Rights Equity Shares to the successful Applicants. All valid Applications after technical rejections have been considered for Allotment.

1. The break-up of application forms received and rejected from the Shareholders and the Renounees is as under:

Category	Gross			Less : Rejections / Partial Amount			Valid		
	Applications	Shares	Amount ()	Applications	Shares	Amount ()	Applications	Shares	Amount ()
Eligible Equity Shareholders	424	812359	109668465.00	69	5957	804195.00	355	806402	108864270.00
Renounees	19	47092	6357420.00	0	0	0.00	19	47092	6357420.00
Total	443	859451	116025885.00	69	5957	804195.00	374	853494	115221690.00

2. Summary of Allotment in various categories is as under:

Category	No. of Applications	Number of Equity Shares Allotted - against Res	Number of Equity Shares Allotted - Against valid additional shares	Total Equity Shares Allotted
Eligible Equity Shareholders	3551	415297	391105	806402
Renounees	19	30419	3650	34069
Total	374	445716	394755	840471

Fractional Entitlements
The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of Seven Rights Equity Shares for every Hundred Fully Paid-up Equity Shares held as on the Record Date on February 03, 2023. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored.

Information for Allotment/ refund / rejected cases : The dispatch of Allotment Advice cum Refund Intimation to the investors, as applicable, has been completed on February 28, 2023. The instructions for unblocking of funds in case of ASBA Applications were issued to SCSBs on February 28, 2023. The listing application was filed with BSE on March 01, 2023. The Company received the listing approval from BSE on March 01, 2023. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form was completed on March 03, 2023. No physical shares were rendered in the Rights Issue. For further details, see "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 168 of the Letter of Offer. The trading in the Rights Equity Shares issued in the Rights Issue shall commence on Stock Exchange upon receipt of trading permission. The trading is expected to commence on or about March 09, 2023. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on March 01, 2023.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN THE DEMATERIALIZED FORM.

DISCLAIMER CLAUSE OF SEBI : It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that the Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 162 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE) : "BSE Limited ("the Exchange") has given vide its letter dated January 19, 2023, permission to this Company to use the Exchange's name in the Letter of Offer as the stock exchange on which this Company's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner • Warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer, or • Warrant that this Company's securities will be listed or will continue to be listed on the Exchange, or • Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company; and it should not for any reason be deemed or construed that this letter of offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 162 of the Letter of Offer. Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
FEDEX SECURITIES PRIVATE LIMITED (CIN: U67120MH1996PTC102140) B7, Jay Chambers, Dayaldas Road, Vile Parle East, Mumbai - 400057. Tel. No.: 91 81049 85249 • E-Mail : mb@fedsec.in • Website : www.fedsec.in Contact Person : Yash Kadakia • SEBI Reg. No.: INM000010163	BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri (East), Mumbai-400059, Maharashtra, India • Tel No.: 022- 62628200,022-626382999 • E-mail : rightissue@bigshareonline.com Website : www.bigshareonline.com • Contact Person : Vijay Surana • SEBI Registration No. : INR000001385
COMPANY SECRETARY AND COMPLIANCE OFFICER	
SHREE GANESH REMEDIES LIMITED • Sunnykumar Narwani • Tel No : +91 7574976076 • E-mail : investors@ganeshremedies.com • Website : www.ganeshremedies.com	

Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), E-mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgements slip (in case of ASBA process). For details on the ASBA process see "Terms of the Issue" on page 167 of the Letter of Offer.

For Shree Ganesh Remedies Limited
 Sunnykumar Narwani
 Company Secretary & Compliance Officer
 Mem No. A38196

Date : 06/03/2023
 Place : Ankleshwar

Disclaimer : Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and Stock Exchange. The Letter of Offer is expected to be available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchange where the Equity Shares are listed i.e. BSE Limited at www.bseindia.com and the website of the Lead Manager at www.fedsec.in. Investors should note that investment in Equity Shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 21 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

HAVE A GOOD BUSINESS MORNING!

Business Standard newspaper delivering safely to homes and offices

For details, SMS reachbs to 57575 or email order@bsmail.in

Business Standard

Insight Out

bsindia bsindia

business-standard.com



ASM TECHNOLOGIES LIMITED

Corporate Identification Number: L85110KA1992PLC013421

Registered Office: 80/2, Lusanne Court, Richmond Road, Bangalore, Karnataka – 560 025, India Tel: +91 80 6696 2300 / 2301
Website: www.asmltd.com E-mail: info@asmltd.com Contact Person: Ms. Vanishree Kulkarni, Company Secretary and Compliance Officer;

This is only an advertisement for information purposes and not publication, distribution or release directly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined here shall have the same meaning assigned to them in the Letter of Offer dated February 15, 2022 filed with BSE Limited ("BSE") (BSE hereinafter referred to as "Stock Exchange").

FIRST AND FINAL CALL MONEY NOTICE TO THE HOLDERS OF PARTLY PAID-UP EQUITY SHARES (ISIN: IN9867C01018) HELD AS ON THE RECORD DATE I.E. TUESDAY, FEBRUARY 21, 2023

In terms of the provisions of the Companies Act, 2013 read with the relevant rules made thereunder, the Letter of Offer dated February 15, 2022, the First and Final Call Notice has been sent in electronic mode to holders of partly paid-up equity shares ("Shareholders"), whose e-mail addresses are registered with the Company or its Registrar and Transfer Agent – Kfin Technologies Limited ("RTA") or the Depository Participant(s) as on the Record Date i.e., Tuesday, February 21, 2023. The First and Final Call Notice along with the detailed instructions and payment slip are also available on the Company's website at www.asmltd.com. Further, physical copies of the First and Final Call Notice along with the detailed instructions and payment slip are being sent to those shareholders: (a) who have not registered their e-mail address with the Company or its RTA or Depository Participant(s); OR (b) who have specifically registered their request for the hard copy of the same. The Company has completed the dispatch on March 06, 2023.

The Board of Directors of the Company ("Board"), at their meeting held on February 08, 2023, had fixed Tuesday, February 21, 2023 as the Record Date for the purpose of determining the holders of partly-paid equity shares to whom the notice for First and Final Call would be sent. The Company has intimated the Record Date the Stock Exchange on February 08, 2023.

Accordingly, the First and Final Call Notice has been served providing the details below:

Payment Period	From	To	Duration
	March 20, 2023	April 05, 2023	
Modes of payment	1) Online ASBA ⁽¹⁾	Through the website of SCSBs(2)	
	2) Physical ASBA ⁽¹⁾	By submitting physical application to the Designated Branch of SCSBs(2)	
	3) Online ⁽¹⁾	Using the 3-in-1 online trading-demat-bank account wherever offered by brokers	

(1) Available only for shareholders holding shares in Demat Mode

(2) Please visit <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35> to refer to the list of existing SCSBs [Self Certified Syndicate Banks]

(3) Only for resident shareholders

In accordance with the SEBI circular no. SEBI/HO/CFD/DIL/1/CIR/238/2020 dated December 8, 2020, shareholders can also make the First and Final Call Money payment by using the facility of linked online trading-demat-bank account (3-in-1 type accounts), provided by some of the brokers. Shareholders must log into their demat account and under the relevant section proceed with the payment for First and Final Call Money of ASM Technologies Limited. Shareholders are requested to check with their respective brokers for exact process to be followed. Shareholders may please note that this payment method can be used only if the concerned broker has made this facility available to their customer. The Company or Registrar will not be responsible for non-availability of this payment method to the shareholders.

Shareholders may please note that, failure to pay the First and Final Call Money, as aforesaid if determined by the Board of Directors of the Company may render the partly paid-up equity shares and the amount already paid thereon liable for forfeiture accordance with the provisions of the Companies Act, 2013 ("Act"), the Articles of Association of the Company and the Letter of Offer.

Shareholders may also note that:

- The ISIN IN9867C01018 representing partly paid-up equity shares of face value ₹10/- each (₹3.00 paid up) has been suspended by the BSE Limited effective February 21, 2023. Further, the ISIN IN9867C01018 representing partly paid-up equity shares of face value ₹10/- each (₹3.00 paid up) has been suspended by National Securities Depository Limited ("NSDL") and Central Depository Services Limited ("CDSL") effective February 22, 2023.
- The process of corporate action for converting the partly paid-up equity shares to the fully paid-up equity shares under the present ISIN IN9867C01018 for the existing fully paid-up equity shares, allotted by the depositories, is estimated to be completed within two to three weeks from the last date of payment of the First and Final Call Money stipulated under this advertisement and the First and Final Call Money Notice. Upon completion of the corporate action, the partly paid-up equity shares shall be converted into fully paid-up equity shares and would be credited to ISIN INE867C01010, allotted by NSDL/CDSL.
- In case of non-receipt of the First and Final Call Notice, shareholders can request by e-mail or letter, for the duplicate First and Final Call Notice to the Registrar, or may also download the same from the Company's website: www.asmltd.com or the Registrar's website: www.kfintech.com. In such a case, however, the shareholder has to fill the DP ID-Client ID, number of partly paid-up equity shares held and amount payable towards the First and Final Call Money;
- This advertisement does not constitute an offer of, or a solicitation of an offer to purchase, any securities of ASM Technologies Limited in any jurisdiction where offers or solicitations are not permitted by law. The information is solely intended for distribution to, and use by, the Shareholders only and is not to be reproduced, transmitted or distributed to any other person;
- The Shareholder must mention in the Application, his/her PAN number allotted under the Income Tax Act, 1961;
- All correspondences in this regard may be addressed to

Kfin Technologies Limited

(formerly known as "Kfin Technologies Private Limited")

Selenium Tower B, Plot no. 31 and 32, Financial District, Nanakramguda, Rangareddy - 500032, Telangana, India
Contact Person: Murali M. Krishna Tel: +91 40 6716 2222; E-mail id: asmltd.rights@kfintech.com

For ASM Technologies Limited
Vanishree Kulkarni
Company Secretary and Compliance Officer
Sunject Comm.

Date: March 06, 2023
Place: Bangalore



(This is an Advertisement for information purposes only and not for publication or distribution or release outside India and is not an Offer Document)

SHREE GANESH REMEDIES LIMITED (CIN : L24230GJ1995PLC025661)

Our Company was originally incorporated as Shree Ganesh Remedies Private Limited at Ahmedabad, Gujarat as a Private Limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated April 27, 1995 bearing registration number 025661 issued by Assistant Registrar of Companies, Gujarat, Dadra & Nagar Haveli. Subsequently our Company was converted into a Public Limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on July 12, 2017 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Gujarat, Ahmedabad dated July 28, 2017 and to consequent legal status the name of our Company was changed to "Shree Ganesh Remedies Limited". Our Company was originally listed on SME platform of BSE Limited on October 13, 2017, subsequently migrated on the Main Board platform of BSE Limited vide their notice dated November 23, 2020. The Corporate Identification Number is L24230GJ1995PLC025661. For further details of our Company, please see section titled as "General Information" beginning on page 39 of the Letter of Offer.

Reg. Off. : Plot no. 6011, G.I.D.C, Ankleshwar, Gujarat - 393002, India. • Tel: +91 7574976076 • E-mail : investors@ganeshremedies.com • Web : www.ganeshremedies.com
Contact Person : Sunnykumar Narwani, Company Secretary & Compliance Officer • Corporate Identification Number : L24230GJ1995PLC025661

PROMOTERS OF OUR COMPANY ARE CHANDULAL KOTHIA, ASHOKKUMAR KOTHIA, MANUBHAI KOTHIYA, GUNJANBHAI KOTHIA & HANSHABEN KOTHIA

ISSUE OF UPTO 8,40,471 PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF 10/- EACH ("RIGHTS EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF 225/- EACH PER RIGHTS EQUITY SHARE (INCLUDING PREMIUM OF 215/- PER EQUITY SHARE) (THE "ISSUE PRICE"), AGGREGATING UPTO 1891.06 LAKHS/- @ ON A RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 7 RIGHTS EQUITY SHARE(S) FOR EVERY 100 FULLY PAID-UP EQUITY SHARE(S) HELD BY THE EXISTING EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON FEBRUARY 03, 2023 (THE "ISSUE"). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARES IS 225/- WHICH IS 22.5 TIMES THE FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE 167 OF THE LETTER OF OFFER.

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on Monday, February 13, 2023 and closed on Tuesday, February 21, 2023 and the last date for On Market Renunciation of Rights Entitlements was Wednesday, February 15, 2023. Out of the total 443 Applications for 8,59,451 Rights Equity Shares, 69 Applications for 5,957 Rights Equity Shares were rejected due to technical reasons. The total number of valid Applications received were 374 for 8,53,494 Rights Equity Shares. In accordance with the Letter of Offer and the Basis of Allotment finalized on February 27, 2023 in consultation with BSE Limited ("BSE"), the Designated Stock Exchange, the Lead Manager to the Issue and the Registrar to the Issue. The Rights Issue Committee of the Company on February 28, 2023 has approved the allotment of 8,40,471 Rights Equity Shares to the successful Applicants. All valid Applications after technical rejections have been considered for Allotment.

1. The break-up of application forms received and rejected from the Shareholders and the Renounees is as under:

Category	Gross			Less : Rejections / Partial Amount			Valid		
	Applications	Shares	Amount ()	Applications	Shares	Amount ()	Applications	Shares	Amount ()
Eligible Equity Shareholders	424	812359	109668465.00	69	5957	804195.00	355	806402	108864270.00
Renounees	19	47092	6357420.00	0	0	0.00	19	47092	6357420.00
Total	443	859451	116025885.00	69	5957	804195.00	374	853494	115221690.00

2. Summary of Allotment in various categories is as under:

Category	No. of Applications	Number of Equity Shares Allotted - against Res	Number of Equity Shares Allotted - Against valid additional shares	Total Equity Shares Allotted
Eligible Equity Shareholders	3551	415297	391105	806402
Renounees	19	30419	3650	34069
Total	374	445716	394755	840471

Fractional Entitlements

The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of Seven Rights Equity Shares for every Hundred Fully Paid-up Equity Shares held as on the Record Date on February 03, 2023. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored.

Information for Allotment / refund / rejected cases : The dispatch of Allotment/Advice cum Refund Intimation to the investors, as applicable, has been completed on February 28, 2023. The instructions for unblocking of funds in case of ASBA Applications were issued to SCSBs on February 28, 2023. The listing application was filed with BSE on March 01, 2023. The Company received the listing approval from BSE on March 01, 2023. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form was completed on March 03, 2023. No physical shares were rendered in the Rights Issue. For further details, see "Terms of the Issue - Allotment/Advice or Refund/Unblocking of ASBA Accounts" on page 168 of the Letter of Offer. The trading in the Rights Equity Shares issued in the Rights Issue shall commence on Stock Exchange upon receipt of trading permission. The trading is expected to commence on or about March 09, 2023. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL/2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on March 01, 2023.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN THE DEMATERIALISATION FORM.

DISCLAIMER CLAUSE OF SEBI : It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that the Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 162 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE) : "BSE Limited (the Exchange)" has given vide its letter dated January 19, 2023, permission to this Company to use the Exchange's name in the Letter of Offer as the stock exchange on which this Company's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner: • Warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer; or • Warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or • Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company; and it should not for any reason be deemed or construed that this letter of offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 162 of the Letter of Offer. Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
FEDEX SECURITIES PRIVATE LIMITED (CIN: U67120MH1996PTC102140) B7, Jay Chambers, Dayaldas Road, Vile Parle East, Mumbai - 400057. Tel. No.: 91 81049 85249 • E-Mail : mb@fedsec.in • Website : www.fedsec.in Contact Person : Yash Kadakia • SEBI Reg. No.: INM00010163	BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri (East), Mumbai-400059, Maharashtra, India • Tel No.: 022- 62628200, 022-626382999 • E-mail : rightissue@bigshareonline.com Website : www.bigshareonline.com • Contact Person : Vijay Surana • SEBI Registration No. : INR00001385
COMPANY SECRETARY AND COMPLIANCE OFFICER	
SHREE GANESH REMEDIES LIMITED • Sunnykumar Narwani • Tel No : +91 7574976076 • E-mail : investors@ganeshremedies.com • Website : www.ganeshremedies.com	

Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), E-mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgements slip (in case of ASBA process). For details on the ASBA process see "Terms of the Issue" on page 167 of the Letter of Offer.

For Shree Ganesh Remedies Limited
Sd/-
Sunnykumar Narwani
Company Secretary & Compliance Officer
Mem No. A38196

Date : 06/03/2023

Place : Ankleshwar

Disclaimer : Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and Stock Exchange. The Letter of Offer is expected to be available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchange where the Equity Shares are listed i.e. BSE Limited at www.bseindia.com and the website of the Lead Manager at www.fedsec.in. Investors should note that investment in Equity Shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 21 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.



ભગવાન મહાવીર કોલેજ ઓફ ફાર્મસી ખાતે ફાર્મા ફિલિક ટેકફેસ્ટ યોજાયો હતો. (તસવીર : મિતેશ)

ભગવાન મહાવીર કોલેજ ઓફ ફાર્મસી ખાતે ફાર્મા ફિલિક ટેકફેસ્ટ યોજાયો

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ ભગવાન મહાવીર કોલેજ ઓફ ફાર્મસી ખાતે ફાર્મા ફિલિક ટેકફેસ્ટ યોજાયો હતો. આ કાર્યક્રમમાં ચીફ ગેસ્ટ તરીકે ગુડહેલ્થ પાર્માસ્યુટિકલ્સ પ્રા. લિ.ના ક્યુએ હેડ એમ. શિવાકુમાર તથા ભગવાન મહાવીર યુનિવર્સિટીના પ્રોવોસ્ટ ડૉ. નિર્મલ શર્મા આમંત્રિત તથા સમાનવિત કરવામાં આવેલ હતો. ફાર્માફિલિક કાર્યક્રમનું આયોજન કોલેજના ડાયરેક્ટર ડૉ. વિનિત જૈન, શ્રીમતી. રશ્મિ કોટ અને શ્રીમતી શેતા દેસાઈ દ્વારા કરવામાં આવેલ હતું. આ કાર્યક્રમમાં સાઉથ ગુજરાત

વેડ રોડ સ્વામિનારાયણ ગુરુકુલમાં હોળીની પૂર્વસંધ્યાએ વ્યસનની હોળી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ હોળી એ દિગ્વિજયનો તહેવાર છે. અધર્મનું આચરણ કરનાર વ્યક્તિને પરાસ્ત કરવા પ્રભુ કોઈ યુક્તિ-પ્રયુક્તિ કરી અધર્મની માહમાયાને દૂર કરે છે. પ્રહલાદજી મૂન્યના મુખમાં ગયા છતાં બચી ગયા. તે દિગ્વિજયને પ્રતિવર્ષ આપણે રંગેરંગે ઉજવીએ છીએ એમ શ્રી દિવ્ય સ્વામીએ કહ્યું હતું. હિરણ્યકશિપુ બાપ જ બેટા પ્રહલાદને મોતના મુખમાં ધેલી દે છે પરંતુ આજે તો માણસ પોતે જ ગુટખા તમાકુ ડ્રગ્સ ખાઈને પોતાના હાથે જ કેન્સર જેવા જટિલ રોગના શિકારી બની શકે છે અને સંપત્તિને મોતના મુખમાં સળગાવી દે છે. પાછળ સંતતિને પણ નિરાધાર કરી દેનાર વ્યસનનો આ વ્યસનો છોડાવનારા શ્રી સ્વામિનારાયણ ગુરુકુલ રાજકોટ સંસ્થાના શાખા સુરત વડેરાડ શ્રી સ્વામિનારાયણ ગુરુકુલના સંતો શ્રી પુરપોતમ સ્વામી તથા સુધોગ સ્વામી તથા સીંગણપોરના પીઆઈ એસ. બી. પાટેરીયા તથા ગુરુકુલ વિદ્યાલયના આચાર્યશ્રી અરવિંદભાઈ દેસાઈ તમજ ભગવાનજીભાઈ કાકડીયા વગેરે એ હોળીની પૂર્વ સંધ્યાએ ગુટકા, માવા, તમાકુ, બીડી, સિગરેટ વગેરેની હોળી કરી હતી.

અખંડ આનંદ કોલેજના અધ્યાપિકા શોભના પ્રજાપતિ પીએચ.ડી. થયા

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ અખંડ આનંદ આર્ટ્સ એન્ડ કોમર્સ કોલેજમાં ફરજ બજાવતા કોમર્સ વિષયના પ્રાધ્યાપિકા શોભના પ્રજાપતિએ કોમર્સ/એકાઉન્ટ પ્રજાપતિએ રજૂ કરેલ મહાશોધ નિબંધ, A Comparative Analysis of Service Quality Gap through RATER Model in Selected New તેમને કોમર્સ/ એકાઉન્ટ-સીના વિષયમાં પીએચ.ડી.ની પદવી એનાયત કરી છે. તેમણે તેમનો મહાશોધ નિબંધ ડો. કિશોરસિંહ એન. ચાવડા વાઈસ ચાન્સેલર, વીર યુનિવર્સિટી, સુરતના માર્ગદર્શન હેઠળ તૈયાર કર્યો હતો.

જીલ્લા કાનૂની સેવા સત્તામંડળ દ્વારા કાનૂની વિષયો પર નિબંધ સ્પર્ધા યોજાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ જીલ્લા કાનૂની સેવા સત્તામંડળ, સુરત અંગત વિભાગ લીટરસી કલબ દ્વારા લુક્સ કોન્વેન્ટ હાઈસ્કૂલ, સુરત ખાતે કાનૂની વિષયો ઉપર યોજાયેલ નિબંધ સ્પર્ધામાં શાળાની પ્રથમ ત્રણ વિજેતા વિદ્યાર્થીનીઓ ને જીલ્લા કાનૂની સેવા સત્તામંડળ, સુરતના સચિવ અને એડિશનલ સિનિયર સિવિલ જજશ્રી સી. આર. મોદી સાહેબશ્રી નાં વરદ હસ્તે ઈનામો આપી સન્માનિત કરવામાં આવ્યા હતા તેમજ એડવોકેટ શ્રી ભરતભાઈ પંડિત એ બેધારણ નું મહત્વ અને સાચાઈ કાઈમ ની સમજ આપી હતી જ્યારે શાળા ના શિક્ષિકા કોરમ શુક્લા એ આવકાર આપ્યો હતો અને નીલાબેન મોદી એ આભાર માન્યો હતો.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.



આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.



આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.

આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ

ધબકાર પ્રતિનિધિ, સુરત, તા. ૦૬ આંતરરાષ્ટ્રીય ખ્યાતિ પ્રાપ્ત તાલ ગ્રુપ દ્વારા વિશ્વ મહિલા દિનની અનોખી ઉજવણી કરાઈ હતી. આ કાર્યક્રમમાં નાયાકા-૨.૦ She Matters નામક આ કાર્યક્રમમાં તાલ ગ્રુપ દ્વારા હોળીની થીમ ઉપર લોકનૃત્યોની રજૂઆત કરાઈ હતી તંદુરપંચ ભારતના ખ્યાતનામ નૃત્યાંગના રુકમણી વિજયકુમારે ભારત નાટ્યમની પ્રસ્તુતિ કરી હતી.

(This is an Advertisement for information purposes only and not for publication or distribution or release outside India and is not an Offer Document)

SHREE GANESH REMEDIES LIMITED (CIN : L24230GJ1995PLC025661)

Our Company was originally incorporated as Shree Ganesh Remedies Private Limited at Ahmedabad, Gujarat as a Private Limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated April 27, 1995 bearing registration number 025661 issued by Assistant Registrar of Companies, Gujarat, Dadra & Nagar Haveli. Subsequently our Company was converted into a Public Limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on July 12, 2017 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Gujarat, Ahmedabad dated July 28, 2017 and to consequent legal status the name of our Company was changed to "Shree Ganesh Remedies Limited". Our Company was originally listed on SME platform of BSE Limited on October 13, 2017, subsequently migrated on the Main Board platform of BSE Limited vide their notice dated November 23, 2020. The Corporate Identification Number is L24230GJ1995PLC025661. For further details of our Company, please see section titled as "General Information" beginning on page 39 of the Letter of Offer.

Reg. Off. : Plot no. 6011, G.I.D.C., Ankleshwar, Gujarat - 393002, India. • Tel: +91 7574976076 • E-mail : investors@ganeshremedies.com • Web : www.ganeshremedies.com
 Contact Person : Sunnykumar Narwani, Company Secretary & Compliance Officer • Corporate Identification Number : L24230GJ1995PLC025661

PROMOTERS OF OUR COMPANY ARE CHANDULAL KOTHIA, ASHOKKUMAR KOTHIA, MANUBHAI KOTHIYA, GUNJANBHAI KOTHIA & HANSHABEN KOTHIA

ISSUE OF UPTO 8,40,471 PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("RIGHTS EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹ 225/- EACH PER RIGHTS EQUITY SHARE (INCLUDING PREMIUM OF ₹215/- PER EQUITY SHARE) (THE "ISSUE PRICE"), AGGREGATING UPTO ₹ 1891.06 LAKHS/- @ ON A RIGHTS BASIS TO THE EXISTING EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 7 RIGHTS EQUITY SHARE(S) FOR EVERY 100 FULLY PAID-UP EQUITY SHARE(S) HELD BY THE EXISTING EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON FEBRUARY 03, 2023 (THE "ISSUE"). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARES IS ₹ 225/- WHICH IS 22.5 TIMES THE FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE 167 OF THE LETTER OF OFFER.

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on Monday, February 13, 2023 and closed on Tuesday, February 21, 2023 and the last date for On Market Renunciation of Rights Entitlements was Wednesday, February 15, 2023. Out of the total 443 Applications for 8,59,451 Rights Equity Shares, 69 Applications for 9,577 Rights Equity Shares were rejected due to technical reasons. The total number of valid Applications received were 374 for 8,53,494 Rights Equity Shares. In accordance with the Letter of Offer and the Basis of Allotment finalized on February 27, 2023 in consultation with BSE Limited ("BSE"), the Designated Stock Exchange, the Lead Manager to the Issue and the Registrar to the Issue. The Rights Issue Committee of the Company on February 28, 2023 has approved the allotment of 8,40,471 Rights Equity Shares to the successful Applicants. All valid Applications after technical rejections have been considered for Allotment.

1. The break-up of application forms received and rejected from the Shareholders and the Renounees is as under:

Category	Gross			Less : Rejections / Partial Amount			Valid		
	Applications	Shares	Amount (₹)	Applications	Shares	Amount (₹)	Applications	Shares	Amount (₹)
Eligible Equity Shareholders	424	812359	109668465.00	69	5957	804195.00	355	806402	108864270.00
Renounees	19	47092	6357420.00	0	0	0.00	19	47092	6357420.00
Total	443	859451	116025885.00	69	5957	804195.00	374	853494	115221690.00

2. Summary of Allotment in various categories is as under:

Category	No. of Applications	Number of Equity Shares Allotted - against Res	Number of Equity Shares Allotted - Against valid additional shares	Total Equity Shares Allotted
Eligible Equity Shareholders	3551	415297	391105	806402
Renounees	19	30419	3650	34069
Total	374	445716	394755	840471

Fractional Entitlements

The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of Seven Rights Equity Shares for every Hundred Fully Paid-up Equity Shares held as on the Record Date on February 03, 2023. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored.

Information for Allotment/ refund / rejected cases : The dispatch of Allotment Advice cum Refund Intimation to the investors, as applicable, has been completed on February 28, 2023. The instructions for unblocking of funds in case of ASBA Applications were issued to SCSBs on February 28, 2023. The listing application was filed with BSE on March 01, 2023. The Company received the listing approval from BSE on March 01, 2023. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form was completed on March 03, 2023. No physical shares were rendered in the Rights Issue. For further details, see "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 168 of the Letter of Offer. The trading in the Rights Equity Shares issued in the Rights Issue shall commence on Stock Exchange upon receipt of trading permission. The trading is expected to commence on or about March 09, 2023. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DILZ/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on March 01, 2023.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN THE DEMATERIALIZATION FORM.

DISCLAIMER CLAUSE OF SEBI : It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that the Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 162 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE) : BSE Limited ("the Exchange") has given vide its letter dated January 19, 2023, permission to this Company to use the Exchange's name in the Letter of Offer as the stock exchange on which this Company's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner : Warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer, or : Warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or : Take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company; and it should not for any reason be deemed or construed that this letter of offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 162 of the Letter of Offer. Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
BEFEX SECURITIES PRIVATE LIMITED (CIN : U67120MH1996PTC102140) B7, Jay Chambers, Dayaldas Road, Vile Parle East, Mumbai - 400057. Tel. No. : 91 81049 85249 • E-Mail : mb@befex.in • Website : www.befex.in Contact Person : Yash Kadakia • SEBI Reg. No. : INM00010163	BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri (East), Mumbai-400059, Maharashtra, India • Tel No. : 022-62628200, 022-626382999 • E-mail : rightissue@bigshareonline.com Website : www.bigshareonline.com • Contact Person : Vijay Surana • SEBI Registration No. : INR000001385
COMPANY SECRETARY AND COMPLIANCE OFFICER	
SHREE GANESH REMEDIES LIMITED • Sunnykumar Narwani • Tel No : +91 7574976076 • E-mail : investors@ganeshremedies.com • Website : www.ganeshremedies.com	

Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), E-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgementslip (in case of ASBA process). For details on the ASBA process see "Terms of the Issue" on page 167 of the Letter of Offer.

For Shree Ganesh Remedies Limited
 Sd/-
 Sunnykumar Narwani
 Company Secretary & Compliance Officer
 Mem No. A38196

Date : 06/03/2023
 Place : Ankleshwar

Disclaimer : Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and Stock Exchange. The Letter of Offer is expected to be available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchange where the Equity Shares are listed i.e. BSE Limited at www.bseindia.com and the website of the Lead Manager at www.fedsec.in. Investors should note that investment in Equity Shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 21 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.